To further explore the underlying mechanism of poor efficacy of ICBs in NSCLC patients with mutations in KEAP1 and FAT1, TCGA cohort was used to compare the differences in immune cell infiltration, neoantigens, TMB, PD-L1 expression, and immune-regulatory mRNA expression between tumors harboring mutations in KEAP1 and FAT1, and those with wild-type genes. This evidence concerns the gene FAT1 and non-small cell lung carcinoma.